161 related articles for article (PubMed ID: 34997277)
21. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
22. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
[TBL] [Abstract][Full Text] [Related]
23. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
24. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
26. [Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Xu W; Li JY; Zhang ZH; Qiu HX; Qian SX; Wu HX; Lu H; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):933-7. PubMed ID: 18718094
[TBL] [Abstract][Full Text] [Related]
27. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
28. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
30. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
34. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
35. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
37. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
38. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols.
Kavan P; Kabickova E; Gajdos P; Koutecky J; Kodet R; McClain KL
Pediatr Hematol Oncol; 1999; 16(3):201-12. PubMed ID: 10326218
[TBL] [Abstract][Full Text] [Related]
39. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
40. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
